Editorial Article
Film Lost Seven Per Cent of Its Units a Year and Two Per Cent of Its Revenue. The Difference Is the Story.
Two numbers describe the same technique, and they differ by almost five points a year.
Between 2025 and 2033, the number of film-based radiographic imaging chains in operation worldwide falls from 26,800 to 14,800 — a decline of 7.15 per cent a year. Over the same eight years, global spending on film radiography falls from USD 1,714 million to USD 1,420 million — a decline of 2.32 per cent a year.
That gap is not an error and it is not a rounding difference. It is the price of film rising 5.20 per cent a year while the number of people buying it falls more than seven. And it is the single most misread feature of the industrial radiography market, because it makes a collapsing technique look like a stable one.
| Film radiography | 2025 | 2033 | CAGR |
|---|---|---|---|
| Imaging chains in operation | 26,800 | 14,800 | −7.15% |
| Spend, USD million | 1,714 | 1,420 | −2.32% |
| Spend per chain, USD | 63,955 | 95,946 | +5.20% |
The repricing was announced, twice
In April 2024, Carestream Health announced worldwide price increases on all of its medical imaging and non-destructive testing films. The language of the announcement is worth reading closely, because it describes a company that had been absorbing costs rather than one that saw an opportunity: the increase was necessary, Carestream said, because of significant increases in the cost of materials used in film manufacturing including silver, energy and other essential resources; the company had absorbed increases in raw materials and energy; it had made ongoing improvements in manufacturing and supply chain; and it had only now begun to raise prices in response to commodity-driven conditions.
The supply side had already thinned years earlier, and it is documented in an unusual place — a NASA technical publication. In its assessment of digital radiography for the Orion Multi-Purpose Crew Vehicle’s tube welds, the NASA Engineering and Safety Center described film as follows: film production is declining, Kodak had all but stopped production, only one primary supplier remained, and the material was getting prohibitively expensive. The agency’s technical lead put the sequence in plain terms — the medical community moved to digital, so film became harder to get.
That is the actual driver of this substitution. Not image quality. Film radiography is not being out-performed; it is being out-supplied, and the price mechanism is how the shortage reaches the buyer.
The metal underneath it
Silver is not a detail in this story; it is the cost line that does the work. After a 147 per cent rally in 2025 and a 42 per cent rise in the annual average price, silver touched an all-time high of USD 121.64 an ounce in January 2026 before easing back to around USD 77, according to Reuters and the Silver Institute. Photovoltaics alone account for 196 million troy ounces, or 17 per cent, of total silver demand, and the solar industry’s response to that price — accelerating substitution toward copper — is a preview of what every silver-consuming industry does when the metal runs.
Film did the same thing, only later and only partly. It passed the cost through. Which is why the film line in this market is shrinking in volume far faster than it is shrinking in dollars.
Why this is bad news dressed as good news
A market where one technique’s revenue declines at half the rate of its volume looks healthier than it is. In our model, film still holds 41.0 per cent of industrial radiography value in 2025 and 21.0 per cent in 2033, and its slow revenue decline props up the topline of the whole market even as the underlying inspection work migrates away.
Two consequences follow, and both matter to anyone with capital at stake.
First, the topline is more fragile than it looks. If silver retreats and film pricing follows, film revenue falls at something closer to its volume rate and the market’s growth rate drops by up to two percentage points with no change whatever in the digital story. A forecast that carries film at a 2.32 per cent decline is carrying a price assumption, not a technology assumption.
Second, the conversion is faster in work than in money. Inspection departments convert when film gets expensive enough to justify the capital. That threshold moves with a metal price they do not control and cannot forecast. It is not a technology-adoption curve, and modelling it as one will get the timing wrong.
The supplier who sells both answers
There is one more thing worth knowing, and it is structural rather than commercial. The firm best placed to convert a film department is frequently the firm selling it the film. The STRUCTURIX radiographic film family — built on what the product documentation still describes as an Agfa emulsion technology, and certified against the German Federal Institute for Materials Research and Testing’s industrial film classification — is sold by Waygate Technologies, which also sells the Phoenix|x-ray range of digital radiography and computed tomography systems.
That is not a conflict of interest. It is a portfolio, and portfolios have a logic: a company earning an annuity on a consumable and a capital sale on its replacement has no reason to accelerate the substitution faster than the consumable’s own economics require. Which means the pace of conversion is set by film supply and film price — not by what the detector can do.
What to watch
Three observables will tell you which way this goes. Silver, because it sets the price mechanism. Film capacity announcements, because investment in a coating line would mean the harvest is over. And any evidence that construction and inspection codes are granting digital qualification routinely rather than project by project — because that, not the detector, is what would genuinely accelerate the switch.
This article draws on the Pheonix Research report Global Industrial Radiography & Digital X-ray Inspection Market, Size, Share and Forecast 2026–2033, which sizes the market at USD 4,180 million in 2025 rising to USD 6,760 million in 2033 at a 6.19 per cent CAGR. Sources cited in-line: Carestream Health’s April 2024 price announcement; NASA NESC’s Orion tube-weld digital radiography assessment and NASA-STD-5009; Reuters and the Silver Institute on silver pricing and demand; Waygate Technologies’ STRUCTURIX and Phoenix|x-ray product documentation. No third-party market estimates are used.
Frequently Asked Questions
Why does film revenue fall so much more slowly than film volume?
Because the two are driven by different things. The chain count follows substitution: buyers moving to computed radiography and digital detector arrays. The revenue line follows price: film manufacturers passing through silver, energy and raw material costs. Carestream repriced its entire global non-destructive testing film line in April 2024 after a period of absorbing those costs, and silver rose 147 per cent in 2025 before touching an all-time high above USD 121 an ounce in January 2026.
Is film radiography being replaced because digital images are better?
Not primarily. Image quality has been table stakes since ISO 17636-2 set minimum digital practice requirements permitting equivalent sensitivity to film. The pressure is commercial: film has become harder to source, as NASA's NESC documented when it found Kodak had all but stopped production and only one primary supplier remained, and the price of what remains has risen with silver. Buyers convert when film gets expensive enough to justify the capital.
What does the film revenue gap mean for the overall market forecast?
It means the market's topline is carrying a price assumption rather than a technology assumption. If silver retreats and film pricing follows, film revenue falls at closer to its volume rate of 7.15 per cent a year rather than 2.32 per cent, and the market's overall growth rate falls by up to two percentage points without any change in the digital story. That is why the realisation line, not the volume line, is the one to stress-test.
What should I watch to know whether the conversion is speeding up?
Watch three things. Silver pricing, because it sets the mechanism. Any announcement of investment in film coating capacity, which would mean the harvest has ended. And evidence that construction and inspection codes are granting digital qualification routinely rather than project by project — because contract-by-contract permission, not detector capability, is what actually gates the conversion.
